

PART - I		STANDALONE			
Sl. No.	PARTICULARS	For the Quarter Ended			For the Year Ended
		30-06-2023	31/03/2023	30-06-2022	31/03/2023
		UN-AUDITED	UN-AUDITED	UN-AUDITED	AUDITED
1	Income				
	Revenue from operations	34,402.56	36,438.99	33,879.91	1,33,007.98
	Other Income	1,005.90	1,075.46	1,089.75	4,455.20
	Total income	35,408.46	37,514.45	34,969.66	1,37,463.18
2	Expenses				
	a) Cost of materials consumed	7,762.36	8,956.75	11,229.40	42,136.24
	b) Changes in inventories of finished goods, work-in-progress and stock-in-trade	2,149.98	2,087.68	(1,564.13)	(2,094.42)
	c) Manufacturing Expenses	3,110.31	3,899.88	4,138.69	17,087.35
	d) Employee benefits expense	2,627.01	2,289.99	2,479.26	10,084.31
	e) R & D expense	208.80	200.89	223.23	858.57
	f) Finance costs	114.65	228.95	143.25	539.17
	g) Depreciation and amortisation expenses	1,114.77	1,062.73	1,054.78	4,284.46
	h) Other Expenses	1,555.91	1,540.99	1,899.49	6,628.17
	Total expenses	18,643.79	20,267.86	19,603.97	79,523.85
3	Profit before exceptional items & Tax (1-2)	16,764.67	17,246.59	15,365.69	57,939.33
4	Exceptional Items	-	-	-	-
5	Profit before Tax (3-4)	16,764.67	17,246.59	15,365.69	57,939.33
6	Tax Expenses				
	a) Current tax	4,131.07	4,296.76	3,888.10	14,462.56
	b) Deferred tax	204.25	150.88	72.42	433.75
	c) Prior year tax	-	(217.23)	-	(217.23)
7	Net Profit/ (Loss) for the period/ year(5-6)	12,429.35	13,016.18	11,405.17	43,260.25
8	Other Comprehensive Income				
8.a	(i) Items that will not be reclassified to profit or loss	1.21	41.29	(25.48)	(35.16)
	(ii) Income tax relating to items that will not be reclassified to profit or loss	(0.30)	(10.39)	6.41	8.85
8.b	(i) Items that will be reclassified to profit or loss	-	-	-	-
	(ii) Income tax relating to items that will be reclassified to profit or loss	-	-	-	-
	Total other Comprehensive Income	0.91	30.90	(19.07)	(26.31)
9	Total Comprehensive Income for the period (7+8)	12,430.26	13,047.08	11,386.10	43,233.94
10	Paid-up equity share capital	2,545.65	2,545.65	2,545.65	2,545.65
	Face Value of the Share	Re. 1.00	Re. 1.00	Re. 1.00	Re. 1.00
11	Other Equity				1,72,392.41
12	Earning Per Share (EPS)-Face value of Rs. 1/- each)				
	a) Basic	4.88	5.11	4.48	16.99
	b) Diluted	4.88	5.11	4.48	16.99
		(not annualised)	(not annualised)	(not annualised)	(annualised)

PART - II		CONSOLIDATED			
Sl. No.	PARTICULARS	For the Quarter Ended			For the Year Ended
		30-06-2023	31/03/2023	30-06-2022	31/03/2023
		UN-AUDITED	UN-AUDITED	UN-AUDITED	AUDITED
1	Income				
	Revenue from operations	34,755.01	36,935.62	33,879.91	1,34,032.88
	Other Income	1,066.51	1,139.95	1,103.31	4,636.38
	Total income	35,821.52	38,075.57	34,983.22	1,38,669.26
2	Expenses				
	a) Cost of materials consumed	7,977.18	9,555.70	11,273.55	43,007.88
	b) Changes in inventories of finished goods, work-in-progress and stock-in-trade	2,149.98	2,087.69	(1,564.13)	(2,094.42)
	c) Manufacturing Expenses	3,227.53	4,046.62	4,230.95	17,628.79
	d) Employee benefits expense	2,874.40	2,560.21	2,658.56	11,051.09
	e) R & D expense	208.80	200.90	223.23	858.57
	f) Finance costs	114.65	230.86	145.16	543.63
	g) Depreciation and amortisation expense	1,254.12	1,195.83	1,150.46	4,773.24
	h) Other Expenses	1,620.55	1,576.67	1,969.53	6,927.50
	Total expenses	19,427.21	21,454.48	20,087.31	82,696.28
3	Profit before exceptional items , Tax & share in profit/(Loss) of Associates (1-2)	16,394.31	16,621.09	14,895.91	55,972.98
4	Add : Share of profit/(Loss) of Associates.	-	-	-	-
5	Profit before exceptional items , Tax (3+4)	16,394.31	16,621.09	14,895.91	55,972.98
6	Exceptional Items	-	-	-	-
7	Profit before Tax (5-6)	16,394.31	16,621.09	14,895.91	55,972.98
8	Tax Expenses				
	a) Current tax	4,131.07	4,290.32	4,069.28	14,627.43
	b) Deferred tax	204.25	150.87	72.42	433.75
	c) Prior year tax	-	(217.23)	-	(217.23)
9	Net Profit/ (Loss) for the period/year(7-8)	12,058.99	12,397.13	10,754.21	41,129.03
10	Other Comprehensive Income				
10.a	(i) Items that will not be reclassified to profit or loss	1.21	49.28	(25.57)	(27.49)
	(ii) Income tax relating to items that will not be reclassified to profit or loss	(0.30)	(10.39)	6.41	8.85
10.b	(i) Items that will be reclassified to profit or loss	-	-	-	-
	(ii) Income tax relating to items that will be reclassified to profit or loss	-	-	-	-
	Total other Comprehensive Income	0.91	38.89	(19.16)	(18.64)
11	Total Comprehensive Income for the period (9 + 10)	12,059.90	12,436.02	10,735.05	41,110.39
12	Paid-up equity share capital Face Value of the Share	2,545.65 Re. 1.00	2,545.65 Re. 1.00	2,545.65 Re. 1.00	2,545.65 Re. 1.00
13	Other Equity				1,70,972.78
14	Earning Per Share (EPS)- (Face value of Rs. 1/- each)				
	a) Basic -	4.74	4.87	4.22	16.16
	b) Diluted	4.74	4.87	4.22	16.16
		(not annualised)	(not annualised)	(not annualised)	(annualised)

Notes 1) The above financial results of the Company have been reviewed by the Audit Committee and approved by the Board of Directors at their respective meetings held on 08th August, 2023. The results for the for the quarter ended 30th June, 2023 has been reviewed by our statutory auditors.

2) The above financial results have been prepared in accordance with the Companies (Indian Accounting Standards) Rules, 2015 (Ind AS) as amended, prescribed under Section 133 of the Companies Act, 2013, read with relevant rules issued thereunder.

3) The consolidated financial results include the results of the wholly owned subsidiaries Suven Pharma, Inc.,USA & Casper Pharma Pvt. Ltd.

4) The Company reportable activity falls under single business segment and hence, segment reporting as per IND AS 108 (Operating Segment) is not presented.

5) The Promoter Group, Jasti Property and Equity Holdings Private Limited (in their capacity as sole trustee of Jasti Family Trust), informed the Company that they executed a Share Purchase Agreement to sell 12,75,37,043 Equity shares representing 50.10% of the Voting share capital to Berhyanda Limited company on 26th December 2022.

6) The corresponding previous period figures have been regrouped/reclassified where ever necessary.

For SUVEN PHARMACEUTICALS LTD

Place : Hyderabad
Date : 8th August 2023

VENKATESWARLU JASTI
Managing Director
DIN: 00278028